Neurogene Statistics
Total Valuation
Neurogene has a market cap or net worth of $714.08 million. The enterprise value is $485.51 million.
| Market Cap | 714.08M |
| Enterprise Value | 485.51M |
Important Dates
The next estimated earnings date is Monday, August 10, 2026, after market close.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Neurogene has 19.93 million shares outstanding. The number of shares has increased by 16.48% in one year.
| Current Share Class | 19.93M |
| Shares Outstanding | 19.93M |
| Shares Change (YoY) | +16.48% |
| Shares Change (QoQ) | +1.01% |
| Owned by Insiders (%) | 7.84% |
| Owned by Institutions (%) | 51.03% |
| Float | 11.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.37 |
| P/TBV Ratio | 3.03 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.08, with a Debt / Equity ratio of 0.04.
| Current Ratio | 13.08 |
| Quick Ratio | 12.90 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -36,879.33 |
Financial Efficiency
Return on equity (ROE) is -37.25% and return on invested capital (ROIC) is -25.13%.
| Return on Equity (ROE) | -37.25% |
| Return on Assets (ROA) | -23.91% |
| Return on Invested Capital (ROIC) | -25.13% |
| Return on Capital Employed (ROCE) | -45.29% |
| Weighted Average Cost of Capital (WACC) | 14.84% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$752,962 |
| Employee Count | 131 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +63.33% in the last 52 weeks. The beta is 1.96, so Neurogene's price volatility has been higher than the market average.
| Beta (5Y) | 1.96 |
| 52-Week Price Change | +63.33% |
| 50-Day Moving Average | 31.73 |
| 200-Day Moving Average | 25.08 |
| Relative Strength Index (RSI) | 52.72 |
| Average Volume (20 Days) | 321,605 |
Short Selling Information
The latest short interest is 3.35 million, so 16.82% of the outstanding shares have been sold short.
| Short Interest | 3.35M |
| Short Previous Month | 3.55M |
| Short % of Shares Out | 16.82% |
| Short % of Float | 30.11% |
| Short Ratio (days to cover) | 16.62 |
Income Statement
| Revenue | n/a |
| Gross Profit | -82.28M |
| Operating Income | -110.64M |
| Pretax Income | -98.64M |
| Net Income | -98.64M |
| EBITDA | -107.45M |
| EBIT | -110.64M |
| Earnings Per Share (EPS) | -$4.56 |
Balance Sheet
The company has $243.18 million in cash and $9.13 million in debt, with a net cash position of $234.05 million or $11.75 per share.
| Cash & Cash Equivalents | 243.18M |
| Total Debt | 9.13M |
| Net Cash | 234.05M |
| Net Cash Per Share | $11.75 |
| Equity (Book Value) | 237.78M |
| Book Value Per Share | 15.23 |
| Working Capital | 227.88M |
Cash Flow
In the last 12 months, operating cash flow was -$82.52 million and capital expenditures -$684,000, giving a free cash flow of -$83.20 million.
| Operating Cash Flow | -82.52M |
| Capital Expenditures | -684,000 |
| Depreciation & Amortization | 3.18M |
| Net Borrowing | -52,000 |
| Free Cash Flow | -83.20M |
| FCF Per Share | -$4.18 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Neurogene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.48% |
| Shareholder Yield | -16.48% |
| Earnings Yield | -13.71% |
| FCF Yield | -11.56% |
Analyst Forecast
The average price target for Neurogene is $81.71, which is 128.02% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $81.71 |
| Price Target Difference | 128.02% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |